Journal of Medicinal Chemistry, 2015, 58(18):7370.DOI:10.1021/acs.jmedchem.5b00726
Caveolin-1 and polymerase I and transcript release factor: new players in insulin-like growth factor-I receptor signaling
We pay special attention to any history of medical conditions, such as medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, to ensure patient safety
Consider semaglutide if: You prioritize lower cost and established safety data You have a history of GI sensitivity and prefer gradual titration You want to start with the more affordable option (semaglutide at $299/month) You're seeking 15-18% weight loss with solid cardiovascular benefit Consider tirzepatide if: You have more aggressive weight loss goals (20%+ reduction) You have type 2 diabetes or significant cardiometabolic risk Cost is not a primary barrier You tolerate GI side effects well or are willing to manage them Many patients find success on either medication
Pro tip : If you go through all the proper steps to try and get a GLP-1 medication covered and still can't get it through your insurance, there are some other options for bringing the cost of medications down
At these doses, liraglutide caused weight loss in rat models [55, 56]